Zobrazeno 1 - 10
of 72
pro vyhledávání: '"F. Picarel-Blanchot"'
Publikováno v:
Advances in Therapy
Introduction The purpose of this study is to investigate the effects of agomelatine on anxious symptoms and functional impairment in a pooled dataset from randomized placebo-controlled trials for generalized anxiety disorder (GAD). Methods Data from
Autor:
Aurore Sors, Ute Marx, Claudio L. Bassetti, Hugues Chabriat, F. Picarel-Blanchot, Dirk M. Hermann, Marine Wattez, Marie-Laure Audoli, Barbara Saba, Celine Gruget
Publikováno v:
Trials
Trials, Vol 21, Iss 1, Pp 1-7 (2020)
Chabriat, Hugues; Bassetti, Claudio L.; Marx, Ute; Picarel-Blanchot, Françoise; Sors, Aurore; Gruget, Celine; Saba, Barbara; Wattez, Marine; Audoli, Marie-Laure; Hermann, Dirk M. (2020). Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study. Trials, 21(1), p. 136. BioMed Central 10.1186/s13063-020-4072-2
Trials, Vol 21, Iss 1, Pp 1-7 (2020)
Chabriat, Hugues; Bassetti, Claudio L.; Marx, Ute; Picarel-Blanchot, Françoise; Sors, Aurore; Gruget, Celine; Saba, Barbara; Wattez, Marine; Audoli, Marie-Laure; Hermann, Dirk M. (2020). Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study. Trials, 21(1), p. 136. BioMed Central 10.1186/s13063-020-4072-2
Background The GABAA-α5 receptor antagonist S44819 is a promising candidate to enhance functional recovery after acute ischemic stroke (IS). S44819 is currently evaluated in this indication; RESTORE brain study started in Dec 2016 and was completed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeeab23d617412ae568ee9f511cc7cb1
Autor:
Jacques Benichou, Marie-Cécile Secouard, Philip Gorwood, Xavier Desobry, F. Picarel-Blanchot, Christian de Bodinat, Nicolas Moore, Marine Wattez
Publikováno v:
Clinical Drug Investigation
Clinical Drug Investigation, Springer Verlag, 2020, ⟨10.1007/s40261-020-00957-9⟩
Clinical Drug Investigation, 2020, ⟨10.1007/s40261-020-00957-9⟩
Clinical Drug Investigation, Springer Verlag, 2020, ⟨10.1007/s40261-020-00957-9⟩
Clinical Drug Investigation, 2020, ⟨10.1007/s40261-020-00957-9⟩
Background and Objectives Non-interventional studies are a valuable source of evidence that is complementary to traditional randomised, blinded and controlled clinical trials, for evaluating antidepressants in a real-world setting. The aim of the pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630908fb98fc2e1178bfe86f783a8134
http://hdl.handle.net/20.500.12278/26013
http://hdl.handle.net/20.500.12278/26013
Publikováno v:
Neuroscience Applied. 1:100212
Publikováno v:
Neuroscience Applied. 1:100142
Publikováno v:
European Neuropsychopharmacology. 40:S59-S60
Publikováno v:
European Neuropsychopharmacology. 40:S186-S187
Autor:
Oleg S. Chaban, Celine Gruget, Christian de Bodinat, Antti Ahokas, A. Avedisova, F. Picarel-Blanchot, Marek Jarema, Dan J. Stein, Valérie Olivier, Livia Vavrusova
Publikováno v:
European Neuropsychopharmacology. 27:526-537
Agomelatine is efficacious in reducing symptoms and preventing relapse in placebo-controlled trials in generalised anxiety disorder (GAD). Nevertheless, fixed dose studies of agomelatine in GAD have not been undertaken. To determine the minimally eff
Publikováno v:
European Neuropsychopharmacology. 40:S60
Publikováno v:
Journal of Affective Disorders
Journal of Affective Disorders, Elsevier, 2016, 199, pp. 6-12. ⟨10.1016/j.jad.2016.03.048⟩
Journal of Affective Disorders, 2016, 199, pp. 6-12. ⟨10.1016/j.jad.2016.03.048⟩
Journal of Affective Disorders, Elsevier, 2016, 199, pp. 6-12. ⟨10.1016/j.jad.2016.03.048⟩
Journal of Affective Disorders, 2016, 199, pp. 6-12. ⟨10.1016/j.jad.2016.03.048⟩
Background A double-blind, randomized, study was conducted in 29 centers in Romania to evaluate the effect of agomelatine 25–50 mg/day (n=144 patients) on general interest, overall clinical efficacy, and functionality in comparison with escitalopra